Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Gene Therapy News

12/6/2024
BreakingEuropeGene TherapyRegulationRetina
EU Grants Orphan Drug Status to Ocugen’s Gene Therapy Candidate for ABCA4-Associated Retinopathies
EU Grants Orphan Drug Status to Ocugen’s Gene Therapy Candidate for ABCA4-Associated Retinopathies

Ocugen announced Nov. 20 that the European Medicines Agency had granted orphan medicinal product status for OCU410ST, a gene therapy candidate targeting ABCA4-associated retinopathies, including St...

11/27/2024
BreakingEuropeGene TherapyRegulationRetina
GenSight Submits Updated Data on Lumevoq to Restart Early Access Program in France
GenSight Submits Updated Data on Lumevoq to Restart Early Access Program in France

Paris-based GenSight Biologics announced Nov. 13 that it had submitted an updated regulatory file for Lumevoq, its gene therapy candidate for Leber hereditary optic neuropathy (LHON), to French reg...

11/27/2024
BreakingDealsGene TherapyRetina
Atsena Licenses LCA1 Gene Therapy Candidate to Nippon Shinyaku for US, Japan
Atsena Licenses LCA1 Gene Therapy Candidate to Nippon Shinyaku for US, Japan

Atsena Therapeutics announced Nov. 13 that it had granted exclusive commercial rights for its Leber congenital amaurosis type 1 (LCA1) gene therapy candidate ATSN-101 to Nippon Shinyaku in the US a...

11/22/2024
BreakingClinical TrialGene TherapyRetina
MeiraGTx to Submit UK Marketing Application for LCA4 Candidate Under ‘Exceptional Circumstances’
MeiraGTx to Submit UK Marketing Application for LCA4 Candidate Under ‘Exceptional Circumstances’

MeiraGTx, with offices in London and New York, announced Nov. 13 that it would submit a marketing authorization application in the UK under “exceptional circumstances” for AAV-AIPL1, its gene thera...

11/14/2024
AAOGene TherapyMeetingNewsletterRetina
Gene Therapies Make Progress Toward Goal of Restoring Sight
Gene Therapies Make Progress Toward Goal of Restoring Sight

Gene therapies again generated buzz at the 2024 AAO meeting—as they have at recent meetings—but perhaps most exciting were reports of a treatment that could partially restore severe vision loss fro...

11/14/2024
AIDealsDiagnosticFundingGene TherapyGlaucomaNewsletterRetinaSurgical
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering

EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...

11/14/2024
DealsGene TherapyNewsletterRetina
The New Opus Genetics Charts a Course to Gene Therapy Approval
The New Opus Genetics Charts a Course to Gene Therapy Approval

Ben Yerxa, PhD, and George Magrath, MD, say they have a way out of the jungle in which ocular gene therapy development has been trapped since the US FDA approved Luxturna in 2017. “You have to be r...

11/14/2024
CataractClinical TrialDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIndustryInstrumentsMicroscopesNewsletterOCTPresbyopiaRegulationRetinaStudySurgical
November 2024 Ophthalmic News Briefs
November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

11/8/2024
BreakingChinaGene TherapyRegulationRetina
US FDA Gives Green Light to Phase I Trial of HuidaGene’s CRISPR RNA-Editing Candidate for Wet AMD
US FDA Gives Green Light to Phase I Trial of HuidaGene’s CRISPR RNA-Editing Candidate for Wet AMD

HuidaGene Therapeutics announced Nov. 4 that the US FDA had cleared its investigational new drug (IND) application for a Phase I trial of HG202, a gene therapy candidate targeting wet age-related m...

10/25/2024
BreakingDealsGene TherapyPresbyopiaRefractiveRetina
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name

Ocuphire Pharma announced Oct. 22 that it would acquire Opus Genetics in an all-stock transaction. The combined company will operate under the Opus name and will trade on the Nasdaq under the ticke...

10/15/2024
Clinical TrialCornealDry EyeGene TherapyGlaucomaIOLNewsletterOcular CancerRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

10/15/2024
ChinaClinical TrialDealsDiagnosticDry EyeEuropeGene TherapyGlaucomaIndiaIndustryLaserNewsletterPerimetryRegulationRetinaSurgical
October 2024 Ophthalmic News Briefs
October 2024 Ophthalmic News Briefs

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...

10/11/2024
BreakingGene TherapyRegulationRetina
Nanoscope Plans to Submit BLA for Optogenetic RP Candidate in Q1-2025
Nanoscope Plans to Submit BLA for Optogenetic RP Candidate in Q1-2025

Nanoscope Therapeutics announced Oct. 10 that it had met with the US FDA regarding MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in patients with advanced retiniti...

10/4/2024
BreakingGene TherapyRegulationRetina
US FDA Grants Orphan Drug Status to Atsena’s XLRS Gene Therapy Candidate
US FDA Grants Orphan Drug Status to Atsena’s XLRS Gene Therapy Candidate

Atsena Therapeutics announced Sept. 17 that ATSN-201, its gene therapy candidate for X-linked retinoschisis (XLRS), had received the US FDA’s orphan drug designation. The candidate was granted rare...

9/27/2024
BreakingGene TherapyIndustryRetina
AAVantgarde Bio Appoints Jayashree Sahni, MD, as Chief Medical Officer
AAVantgarde Bio Appoints Jayashree Sahni, MD, as Chief Medical Officer

Italy’s AAVantgarde Bio announced Sept. 9 that it had appointed Jayashree Sahni, MD, FRCOphth, EMBA, as chief medical officer. Sahni, a retina specialist, was senior global program clinical head at...

9/19/2024
CataractFundingGene TherapyMyopiaNewsletterPharmaRetina
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round

ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...

9/19/2024
Dry EyeEmergingGene TherapyNewsletterRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, September 2024
Emerging Companies Pursuing Ophthalmic Indications, September 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

9/19/2024
AmblyopiaClinical TrialDiagnosticFundusGene TherapyGlaucomaIndustryNewsletterRegulationRetinaSurgical
September 2024 Ophthalmic News Briefs
September 2024 Ophthalmic News Briefs

Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...

9/13/2024
BreakingGene TherapyRegulationRetina
US FDA Grants Orphan Drug Status to Skyline’s Gene Therapy Candidate for RP
US FDA Grants Orphan Drug Status to Skyline’s Gene Therapy Candidate for RP

China’s Skyline Therapeutics announced Sept. 3 that the US FDA had granted orphan drug designation to SKG1108, an intravitreal gene therapy candidate for retinitis pigmentosa (RP). SKG1108 is a rec...

9/6/2024
BreakingEmergingGene TherapyRetina
Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease 
Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease

Tern Therapeutics announced its launch Aug. 27, along with closing of a $15 million financing. The company also reported that it had licensed gene therapy candidates RGX-381 and RGX-181 (now design...

9/6/2024
BreakingClinical TrialGene TherapyRegulationRetina
Health Canada Gives Green Light to Phase III Trial of Ocugen’s Gene Therapy Candidate for RP
Health Canada Gives Green Light to Phase III Trial of Ocugen’s Gene Therapy Candidate for RP

Ocugen announced Aug. 26 that Health Canada had cleared the way for a Canadian Phase III trial of OCU400, a modifier gene therapy candidate for retinitis pigmentosa (RP). Ocugen, of Malvern, Pennsy...

8/23/2024
BreakingGene TherapyRegulationRetina
US FDA Grants Rare Pediatric Disease Designation to Atsena’s X-Linked Retinoschisis Gene Therapy Candidate
US FDA Grants Rare Pediatric Disease Designation to Atsena’s X-Linked Retinoschisis Gene Therapy Candidate

Atsena Therapeutics announced Aug. 14 that ATSN-201, its gene therapy candidate for X-linked retinoschisis (XLRS), had received the US FDA’s rare pediatric disease designation. XLRS is a monogenic ...

8/23/2024
BreakingGene TherapyRegulationRetina
US FDA Grants Rare Pediatric Disease Designation to Opus’ LCA5 Gene Therapy Candidate
US FDA Grants Rare Pediatric Disease Designation to Opus’ LCA5 Gene Therapy Candidate

Opus Genetics announced Aug. 20 that OPGx-LCA5, its gene therapy candidate for Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene, had received the US FDA’s rare p...

8/23/2024
BreakingGene TherapyIndustryRetina
SalioGen Therapeutics Appoints Kali Stasi, MD, PhD, as Chief Medical Officer
SalioGen Therapeutics Appoints Kali Stasi, MD, PhD, as Chief Medical Officer

SalioGen Therapeutics announced Aug. 19 that it had appointed Kalliopi “Kali” Stasi, MD, PhD, as chief medical officer. SalioGen said Stasi will be responsible for bringing the company’s SGT-1001, ...

8/21/2024
DiagnosticDry EyeFundingGene TherapyLaserNewsletterRetina
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering

MeiraGTx led recent ophthalmic fundraising efforts with a $50 million offering of ordinary shares as it moves forward with its extensive pipeline of gene therapy candidates. Financing announced in ...

8/21/2024
Clinical TrialDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2024
Clinical Trial Updates for Ophthalmic Candidates, August 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

8/21/2024
BiosimilarsCornealDealsDry EyeEuropeGene TherapyGenericsIndustryLow VisionNewsletterOcular CancerPharmaPresbyopiaRegulationRetina
August 2024 Ophthalmic News Briefs
August 2024 Ophthalmic News Briefs

Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...

8/16/2024
BreakingFundingGene TherapyRegulationRetina
US FDA Approves Expanded Access Program for Ocugen’s RP Candidate
US FDA Approves Expanded Access Program for Ocugen’s RP Candidate

Ocugen announced Aug. 5 that the US FDA had approved an expanded access program to allow for the treatment of adults with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candi...

8/2/2024
BreakingGene TherapyRegulationRetina
Adverum Receives US FDA’s RMAT Designation for Ixo-vec in Wet AMD
Adverum Receives US FDA’s RMAT Designation for Ixo-vec in Wet AMD

Adverum Biotechnologies announced Aug. 1 that Ixo-vec, its intravitreal gene therapy candidate for wet age-related macular degeneration (AMD), had received the US FDA’s regenerative medicine advanc...

7/26/2024
BreakingGene TherapyIndustryRetina
Beacon Appoints Lance Baldo, MD, as Chief Executive Officer
Beacon Appoints Lance Baldo, MD, as Chief Executive Officer

Beacon Therapeutics announced July 24 that it had named Lance Baldo, MD, as chief executive officer, effective Aug. 12, 2024. Most recently, Baldo served as chief medical officer at Freenome, an ea...

7/23/2024
BiosimilarsCornealFundingGene TherapyMyopiaNewsletterPresbyopiaRetina
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B

Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...

7/23/2024
ChinaEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, July 2024
Emerging Companies Pursuing Ophthalmic Indications, July 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

7/23/2024
Clinical TrialDry EyeGene TherapyIOLNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2024
Clinical Trial Updates for Ophthalmic Candidates, July 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

7/23/2024
BiosimilarsClinical TrialCornealDealsDry EyeEuropeGene TherapyGlaucomaIndiaIndustryMyopiaNewsletterRegulationRetina
July 2024 Ophthalmic News Briefs
July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/19/2024
BreakingDealsGene TherapyRetina
Beacon Will Evaluate Abeona’s AAV204 Capsid for Select Ophthalmic Indications
Beacon Will Evaluate Abeona’s AAV204 Capsid for Select Ophthalmic Indications

Beacon Therapeutics will evaluate Abeona Therapeutics’ patented AAV204 capsid for potential gene therapies for select ophthalmic indications, the companies announced July 11. AAV204, a novel AAV ca...

6/28/2024
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of 4DMT’s Gene Therapy Candidate for GA
US FDA Gives Green Light to Trial of 4DMT’s Gene Therapy Candidate for GA

4D Molecular Therapeutics announced June 24 that the US FDA had cleared its investigational new drug application for a Phase I clinical trial of 4D-175, an intravitreal gene therapy candidate targe...

6/24/2024
DealsDiagnosticFundingGene TherapyGlaucomaNewsletterPharmaRetinaTelehealth
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer

Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...

6/24/2024
CataractClinical TrialData SecurityDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryMyopiaNewsletterRefractiveRegulationRetinaSurgical
June 2024 Ophthalmic News Briefs
June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

6/21/2024
BreakingGene TherapyRetina
Opus Genetics, Abu Dhabi to Collaborate on Retinal Gene Therapies in UAE
Opus Genetics, Abu Dhabi to Collaborate on Retinal Gene Therapies in UAE

Opus Genetics and Abu Dhabi’s Department of Health announced June 5 that they had agreed to collaborate on the development of gene therapies for patients with rare inherited retinal diseases in the...

6/14/2024
BreakingGene TherapyIndustryRetina
Regenxbio Appoints Simpson as President, CEO; Co-founder Mills Transitions to Chairman
Regenxbio Appoints Simpson as President, CEO; Co-founder Mills Transitions to Chairman

Regenxbio announced June 12 that its chief operating officer, Curran Simpson, had been appointed president and chief executive officer. He will also join the board of directors. Co-founder Kenneth ...

6/7/2024
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Avirmax’ Gene Therapy Candidate for Wet AMD with PCV
US FDA Gives Green Light to Trial of Avirmax’ Gene Therapy Candidate for Wet AMD with PCV

Avirmax Biopharma announced May 30 that the US FDA had cleared its investigational new drug application for a Phase I/IIa clinical trial of its intravitreal gene therapy candidate targeting wet age...

5/22/2024
CataractGene TherapyMeetingNewsletterRetina
2024 ARVO Meeting Sets Attendance Record, Showcases Novel Treatment Approaches
2024 ARVO Meeting Sets Attendance Record, Showcases Novel Treatment Approaches

The 2024 meeting of the Association for Research in Vision and Ophthalmology set a record as the largest ARVO meeting ever. The 11,631 registered attendees passed the old record of 10,224 set in Va...

5/22/2024
AICataractDiagnosticFundingGene TherapyGlaucomaIOLNewsletterRetina
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering

RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...

5/22/2024
CornealDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterOcular CancerRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Emerging Companies Pursuing Ophthalmic Indications, May 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

5/22/2024
Clinical TrialGene TherapyIOLIndustryMeetingNewsletterRetinaStudy
Ophthalmic Companies Use ARVO Meeting to Boost Research
Ophthalmic Companies Use ARVO Meeting to Boost Research

Many companies participate in ARVO’s annual meeting to catch the attention of external researchers and propel their research program or clinical trials forward. Two such companies in 2024 were John...

5/22/2024
CataractClinical TrialCornealGene TherapyGlaucomaNewsletterPharmaRefractiveRetina
Clinical Trial Updates for Ophthalmic Candidates, May 2024
Clinical Trial Updates for Ophthalmic Candidates, May 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

4/24/2024
Clinical TrialCornealGene TherapyGlaucomaLow VisionNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates , April 2024
Clinical Trial Updates for Ophthalmic Candidates , April 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

4/24/2024
Clinical TrialGene TherapyNewsletterRetina
Nanoscope Reports Positive Results for RP Optogenetic Therapy
Nanoscope Reports Positive Results for RP Optogenetic Therapy

Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monother-apy to restore vision i...

4/19/2024
BreakingGene TherapyRetina
SalioGen Selects Gene Therapy Candidate to Develop for Stargardt
SalioGen Selects Gene Therapy Candidate to Develop for Stargardt

SalioGen Therapeutics announced April 17 that it had chosen a development candidate, SGT-1001, for the treatment of Stargardt disease. SGT-1001 is being developed as a one-time, non-viral gene ther...

4/12/2024
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate

Ocugen announced April 8 that the US FDA had cleared the company’s investigational new drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy candidate for r...

3/29/2024
BreakingClinical TrialGene TherapyRegulationRetina
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024

Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in...

3/21/2024
Clinical TrialDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, March 2024
Clinical Trial Updates for Ophthalmic Candidates, March 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

3/21/2024
Gene TherapyNewsletterRetinaStudy
Oculogenex’ Preclinical Retinal Gene Therapy Heads to Space for Study in Mice
Oculogenex’  Preclinical Retinal Gene Therapy Heads to Space  for Study in Mice

Oculogenex, a California company developing a regenerative gene therapy for age-related macular degeneration (AMD), is sending its preclinical work into space. The company’s gene therapy candidate ...

3/21/2024
AllergyDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, March 2024
Emerging Companies Pursuing Ophthalmic Indications, March 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

3/8/2024
BreakingGene TherapyRetinaStudy
Oculogenex’ Preclinical Retinal Gene Therapy Heads to Space with Mouse Model
Oculogenex’ Preclinical Retinal Gene Therapy Heads to Space with Mouse Model

Oculogenex, a California company developing a regenerative gene therapy for age-related macular degeneration (AMD), is sending its preclinical work into space. The company’s gene therapy candidate ...

3/1/2024
BreakingEmergingGene TherapyRetina
France’s PulseSight Therapeutics Launches to Advance Non-viral Retinal Gene Therapies
France’s PulseSight Therapeutics Launches to Advance Non-viral Retinal Gene Therapies

France’s PulseSight Therapeutics, developing non-viral ophthalmic gene therapies, launched Feb. 28 with an undisclosed seed financing from Pureos Bioventures and ND Capital. A spokeswoman for Pulse...

2/22/2024
DealsFundingGene TherapyGlaucomaNewsletterRetinaSurgical
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering

4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...

2/22/2024
Clinical TrialGene TherapyNewsletterRetina
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Wet AMD Trial
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Wet AMD Trial

4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...

2/22/2024
CataractClinical TrialCornealDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryNewsletterPresbyopiaRegulationRetinaSurgical
February 2024 Ophthalmic News Briefs
February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

2/9/2024
BreakingFundingGene TherapyRetina
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Trial for Wet AMD
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Trial for Wet AMD

4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...

2/2/2024
BreakingClinical TrialGene TherapyRegulationRetina
Ascidian’s Stargardt Candidate is First RNA Exon Editor to Gain FDA’s Green Light for Trial
Ascidian’s Stargardt Candidate is First RNA Exon Editor to Gain FDA’s Green Light for Trial

Ascidian Therapeutics announced Jan. 29 that the US FDA had cleared a Phase I/II clinical trial for its ACDN-01 RNA exon editor for Stargardt disease and other ABCA4 retinopathies. It’s the first g...

1/23/2024
CataractClinical TrialDry EyeGene TherapyGlaucomaNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, January 2024
Clinical Trial Updates for Ophthalmic Candidates, January 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

1/23/2024
DealsGene TherapyNewsletterRetina
Janssen Purchases Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million
Janssen Purchases  Remaining Rights  for XLRP Candidate from MeiraGTx for $415 Million

Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercializa-tion of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx r...

1/23/2024
CataractCornealDealsDry EyeGene TherapyGlaucomaIndustryLaserNewsletterOCTRegulationRetina
January 2024 Ophthalmic News Briefs
January 2024 Ophthalmic News Briefs

Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...

1/19/2024
BreakingGene TherapyRegulationRetina
US FDA Grants Rare Pediatric Disease Designation to Atsena’s LCA1 Gene Therapy Candidate
US FDA Grants Rare Pediatric Disease Designation to Atsena’s LCA1 Gene Therapy Candidate

Atsena Therapeutics announced Jan. 16 that its gene therapy candidate for Leber congenital amaurosis 1, ATSN-101, had received the US FDA’s rare pediatric disease designation. The candidate had alr...

1/12/2024
BreakingGene Therapy
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
Kriya Announces Gene Therapy Program for Thyroid Eye Disease

Kriya Therapeutics announced Jan. 5 that it had added to its pipeline a gene therapy candidate for thyroid eye disease (TED). TED is an autoimmune condition that can cause proptosis (eye bulging) a...

1/5/2024
BreakingGene TherapyRegulationRetina
4DMT Receives US FDA’s RMAT Designation for Wet AMD Gene Therapy Candidate
4DMT Receives US FDA’s RMAT Designation for Wet AMD Gene Therapy Candidate

4D Molecular Therapeutics announced Dec. 21 that 4D-150, its intravitreal gene therapy candidate targeting wet age-related macular degeneration (AMD), had received the US FDA’s regenerative medicin...

1/5/2024
BreakingGene TherapyIndustryRetina
SpliceBio Appoints Aniz Girach, MD, as Chief Medical Officer
SpliceBio Appoints Aniz Girach, MD, as Chief Medical Officer

Spain’s SpliceBio announced Jan. 3 that it had appointed Aniz Girach, MD, as chief medical officer. SpliceBio’s protein splicing platform offers the potential to address diseases where the genetic ...

12/29/2023
BreakingDealsGene TherapyRetina
Janssen Buys Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million
Janssen Buys Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million

Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercialization of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx re...

12/14/2023
BiosimilarsEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, December 2023
Emerging Companies Pursuing Ophthalmic Indications, December 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

12/14/2023
CataractClinical TrialDealsDiagnosticGene TherapyGlaucomaIndustryNewsletterRegulationRetinaTelehealth
December 2023 Ophthalmic News Briefs
December 2023 Ophthalmic News Briefs

Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...

12/1/2023
BreakingGene TherapyIndustryRetina
Generation Bio Drops Retinal Candidates, Cuts Workforce
Generation Bio Drops Retinal Candidates, Cuts Workforce

Generation Bio, of Cambridge, Massachusetts, reported Nov. 29 that it would stop advancing its pipeline of retinal candidates as it redefines its strategic priorities and reduces its workforce by 4...

11/21/2023
CornealDiagnosticEmergingGene TherapyGlaucomaNewsletterRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, November 2023
Emerging Companies Pursuing Ophthalmic Indications, November 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

11/21/2023
ChinaDealsDiagnosticDry EyeGene TherapyGenericsGlaucomaIndustryNewsletterPresbyopiaRegulationRetinaSurgical
November 2023 Ophthalmic News Briefs
November 2023 Ophthalmic News Briefs

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...

11/17/2023
BreakingGene TherapyRegulationRetina
Atsena Receives FDA’s RMAT Designation for LCA1 Gene Therapy Candidate
Atsena Receives FDA’s RMAT Designation for LCA1 Gene Therapy Candidate

Atsena Therapeutics announced Nov. 14 that its gene therapy candidate for Leber congenital amaurosis 1, ATSN-101, had received the US FDA’s regenerative medicine advanced therapy (RMAT) designation...

11/10/2023
BreakingGene TherapyIndustryRetina
Regenxbio Says it Will Cut Staff, Realign Pipeline Priorities to Extend Cash Runway
Regenxbio Says it Will Cut Staff, Realign Pipeline Priorities to Extend Cash Runway

Regenxbio announced in its Q3-2023 financial statement on Nov. 8 that it would cut its workforce by approximately 15 percent while prioritizing three gene therapy candidates with the largest commer...

11/10/2023
BreakingFundingGene TherapyIndustryRetina
Ascidian Raises $40 Million in Series A Funding, Appoints Michael Ehlers as Interim President, CEO
Ascidian Raises $40 Million in Series A Funding, Appoints Michael Ehlers as Interim President, CEO

Ascidian Therapeutics announced Nov. 8 that it had raised $40 million in Series A extension funding from life sciences venture capital company Apple Tree Partners. Ascidian, of Boston, Massachusett...

10/27/2023
BreakingChinaClinical TrialGene TherapyRetina
Chinese Regulators Give Green Light to Skyline for Trial of Gene Therapy Candidate for Wet AMD
Chinese Regulators Give Green Light to Skyline for Trial of Gene Therapy Candidate for Wet AMD

China’s Skyline Therapeutics announced Oct. 19 that the National Medical Products Administration had cleared its investigational new drug application for a clinical trial of SKG0106, a one-time int...

10/24/2023
FundingGene TherapyMeetingNewsletterRefractive
Futures Forums Cater to Companies that Can’t Gain Limelight Elsewhere, Co-founder Says
Futures Forums Cater to Companies that Can’t Gain Limelight Elsewhere, Co-founder Says

Kuldev Singh, MD (US), co-founder of Europe’s annual Ophthalmology Futures Forums (OFF), told Market Scope in October that he takes pride in the group’s record of giving “people with new ideas who ...

10/24/2023
DealsDry EyeGene TherapyNewsletter
Acquisitions and OUS Investments Drive Ophthalmic Deals in Third Quarter of 2023
Acquisitions and OUS Investments Drive Ophthalmic Deals in Third Quarter of 2023

Ophthalmic deals in Q3-2023 reached nearly $2.8 billion and involved 22 transactions. This compares with $6.9 billion from 24 transactions in Q2-2023 and $1.0 billion from 20 transactions in Q3-202...

10/24/2023
Clinical TrialDry EyeGene TherapyNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2023
Clinical Trial Updates for Ophthalmic Candidates, October 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

10/24/2023
CataractClinical TrialDealsDiagnosticDry EyeGene TherapyGenericsIOLIndustryMicroscopesNewsletterOcular CancerRegulationRetina
October 2023 Ophthalmic News Briefs
October 2023 Ophthalmic News Briefs

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

10/24/2023
ChinaDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, October 2023
Emerging Companies Pursuing Ophthalmic Indications, October 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

10/20/2023
BreakingDealsGene TherapyRetina
SpliceBio, Spark Therapeutics to Collaborate on Gene Therapy Targeting Inherited Retinal Disease
SpliceBio, Spark Therapeutics to Collaborate on Gene Therapy Targeting Inherited Retinal Disease

Spain’s SpliceBio announced Oct. 17 that it had signed an agreement with Spark Therapeutics to utilize SpliceBio’s protein splicing platform to develop a gene therapy for an undisclosed inherited r...

9/29/2023
BreakingDealsGene TherapyRetina
Kriya Licenses Everads’ Suprachoroidal Delivery Technology for Gene Therapy Candidates Targeting Complement Cascade
Kriya Licenses Everads’ Suprachoroidal Delivery Technology for Gene Therapy Candidates Targeting Complement Cascade

Israel’s Everads Therapy announced Sept. 27 that it had entered into an agreement with Kriya Therapeutics to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ supracho...

9/29/2023
BreakingDealsGene TherapyRetina
ProQR’s Deal with Théa to Acquire Ophthalmic Assets is Terminated
ProQR’s Deal with Théa to Acquire Ophthalmic Assets is Terminated

Netherlands-based ProQR Therapeutics announced Sept. 27 that a deal with France’s Laboratoires Théa to acquire ProQR’s late-stage ophthalmic assets had been terminated. Théa had agreed in August 20...

9/22/2023
BreakingGene TherapyIndustryRetina
Nanoscope Appoints Samuel Barone, MD, as Chief Medical Officer
Nanoscope Appoints Samuel Barone, MD, as Chief Medical Officer

Nanoscope Therapeutics, of Dallas, announced Sept. 21 that it had appointed Samuel Barone, MD, as chief medical officer. Barone was most recently chief medical officer at Gemini Therapeutics, prior...

9/21/2023
CataractCornealDry EyeFundingGene TherapyNewsletterPharmaRetina
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue

Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...

9/21/2023
Gene TherapyNewsletterRetina
Novartis Drops Gene Therapy Candidate for GA Acquired in Gyroscope Deal
Novartis Drops Gene Therapy Candidate for GA Acquired in Gyroscope Deal

UK life sciences investment firm Syncona reported on Sept. 11 that Novartis had decided to discontinue development of geographic atrophy (GA) gene therapy candidate GT005, which it acquired in Dece...

9/21/2023
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, September 2023
Clinical Trial Updates for Ophthalmic Candidates, September 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

9/21/2023
ChinaClinical TrialCornealDealsDiagnosticDry EyeEuropeGene TherapyIndustryNewsletterRefractiveRegulationRetinaSurgical
September 2023 Ophthalmic News Briefs
September 2023 Ophthalmic News Briefs

Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...

9/15/2023
BreakingGene TherapyRetina
Novartis Discontinues Development of GA Gene Therapy Candidate Acquired in Gyroscope Deal
Novartis Discontinues Development of GA Gene Therapy Candidate Acquired in Gyroscope Deal

UK life sciences investment firm Syncona reported on Sept. 11 that Novartis had decided to discontinue development of geographic atrophy (GA) gene therapy candidate GT005, which it acquired in Dece...

9/15/2023
BreakingDealsGene TherapyRetina
Otsuka, ShapeTX Will Collaborate on Ocular Gene Therapy Candidates
Otsuka, ShapeTX Will Collaborate on Ocular Gene Therapy Candidates

Japan’s Otsuka Pharmaceutical and ShapeTX announced Sept. 7 that they would collaborate to develop intravitreally delivered adeno-associated virus (AAV) gene therapy candidates for ocular diseases,...

9/8/2023
BreakingChinaClinical TrialGene TherapyRegulationRetina
Neurophth Gets Green Light from Australian Regulators for Trial of Ophthalmic Gene Therapy Candidate
Neurophth Gets Green Light from Australian Regulators for Trial of Ophthalmic Gene Therapy Candidate

Neurophth Therapeutics announced Sept. 6 that the Australian Therapeutic Goods Administration had cleared its gene therapy candidate NFS-05 for clinical trials targeting autosomal dominant optic at...

8/25/2023
BreakingClinical TrialEuropeGene TherapyRegulationRetina
EMA Gives Green Light to Phase Ib Trial of ViGeneron’s Gene Therapy Candidate for RP
EMA Gives Green Light to Phase Ib Trial of ViGeneron’s Gene Therapy Candidate for RP

Germany’s ViGeneron announced Aug. 22 that the European Medicines Agency (EMA) had approved its clinical trial application for VG901, a gene therapy candidate targeting CNGA1-associated retinitis p...

8/22/2023
CataractCornealDry EyeFundingGene TherapyIOLNewsletterPharmaRetinaSurgical
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C

Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....

8/22/2023
Gene TherapyIndustryNewsletter
Gene Therapy Developer Intergalactic Therapeutics Lays Off All Employees
Gene Therapy Developer Intergalactic Therapeutics Lays Off All Employees

Boston-headquartered Intergalactic Therapeutics has laid off all its employees and is exploring options, the Boston Business Journal reported Aug. 1. Intergalactic was developing a non-viral gene t...

8/10/2023
BreakingGene TherapyRegulationRetina
US FDA Grants Rare Pediatric Disease Designation to HuidaGene’s RPE65 Gene Therapy Candidate
US FDA Grants Rare Pediatric Disease Designation to HuidaGene’s RPE65 Gene Therapy Candidate

HuidaGene Therapeutics announced Aug. 7 that the US FDA had given rare pediatric disease designation to HG004, a gene therapy candidate for inherited retinal dystrophies associated with the RPE65 m...

8/4/2023
BreakingGene TherapyIndustryRetina
Gene Therapy Developer Intergalactic Therapeutics Lays Off All Employees
Gene Therapy Developer Intergalactic Therapeutics Lays Off All Employees

Boston-headquartered Intergalactic Therapeutics has laid off all its employees and is exploring options, the Boston Business Journal reported Aug. 1. Intergalactic was developing a non-viral gene t...

8/4/2023
BreakingGene TherapyIndustryRetina
Complement Therapeutics Appoints Parisa Zamiri, MD, PhD, as Chief Medical Officer
Complement Therapeutics Appoints Parisa Zamiri, MD, PhD, as Chief Medical Officer

Complement Therapeutics (CTx) announced Aug. 3 that it had appointed Parisa Zamiri, MD, PhD, as chief medical officer. Zamiri is an ophthalmologist by training, with clinical experience in medical ...

7/25/2023
DealsGene TherapyNewsletterRetina
Astellas Licenses 4DMT’s Intravitreal Gene Therapy Vector in Deal Potentially Worth Nearly $1 Billion
Astellas Licenses 4DMT’s Intravitreal Gene Therapy Vector in Deal Potentially Worth Nearly $1 Billion

Japan’s Astellas Pharma and 4D Molecular Therapeutics announced July 10 that Astellas is licensing 4DMT’s R100 intravitreal gene therapy vector for one rare inherited ophthalmic disease, with optio...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more